Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Transplantation. 2011 Dec 27;92(12):1301-8. doi: 10.1097/TP.0b013e318237d6d4.
Mixed donor-host chimerism, established through hematopoietic cell transplantation (HCT), is a reproducible strategy for the induction of tolerance toward solid organs. Here, we ask whether a nonmyeloablative conditioning regimen establishing mixed donor-host chimerism leads to tolerance of antigenic vascularized composite allografts.
Stable mixed chimerism was established in dogs given a sublethal dose (1-2 Gy) total body irradiation before and a short course of immunosuppression after dog leukocyte antigen-identical marrow transplantation. Vascularized composite allografts from marrow donors were performed after a median of 36 months (range, 4-54 months) after HCT.
All marrow recipients maintained mixed donor-host hematopoietic chimerism and accepted vascularized composite allografts for periods ranging between 52 and 90 weeks; in turn, marrow donors rejected vascularized composite allografts from their respective marrow recipients within 18 to 29 days. Biopsies of muscle and skin of vascularized composite allografts from mixed chimeras showed few infiltrating cells compared with extensive infiltrates in biopsies of vascularized composite allografts from marrow donors. Elevated levels of CD3+ FoxP3+ T-regulatory cells were found in skin and muscle of vascularized composite allografts of mixed chimeras compared with normal tissues. In mixed chimeras, increased numbers of T-regulatory cells were found in draining compared with nondraining lymph nodes of vascularized composite allografts.
These data suggest that nonmyeloablative HCT may form the basis for future clinical applications of solid organ transplantation and that T-regulatory cells may function toward maintenance of the vascularized composite allograft.
通过造血细胞移植(HCT)建立的混合供体-宿主嵌合体是诱导对实体器官耐受的一种可重复的策略。在这里,我们询问非清髓性预处理方案建立混合供体-宿主嵌合体是否会导致对抗原性血管化复合同种异体移植物的耐受。
在犬白细胞抗原匹配的骨髓移植前给予亚致死剂量(1-2Gy)全身照射,并在骨髓移植后短期给予免疫抑制,稳定建立混合嵌合体。在 HCT 后中位数为 36 个月(范围,4-54 个月)后,进行来自骨髓供体的血管化复合同种异体移植物。
所有骨髓受者均维持混合供体-宿主造血嵌合体,并接受血管化复合同种异体移植物,时间范围为 52 至 90 周;相反,骨髓供者在 18 至 29 天内从各自的骨髓受者中排斥血管化复合同种异体移植物。与骨髓供者的血管化复合同种异体移植物活检相比,混合嵌合体的血管化复合同种异体移植物的肌肉和皮肤活检显示浸润细胞较少。与正常组织相比,在混合嵌合体的血管化复合同种异体移植物的皮肤和肌肉中发现了较高水平的 CD3+FoxP3+T 调节细胞。在混合嵌合体中,与非引流淋巴结相比,血管化复合同种异体移植物引流淋巴结中的 T 调节细胞数量增加。
这些数据表明,非清髓性 HCT 可能为未来的实体器官移植的临床应用奠定基础,并且 T 调节细胞可能对维持血管化复合同种异体移植物起作用。